

**RECEIVED  
CENTRAL FAX CENTER****OCT 26 2006****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>In re United States Patent Application of:</b>	)	<b>Docket No.:</b>	<b>4179-123</b>
	)		
<b>Applicants:</b>	)	<b>Conf. No.:</b>	<b>4204</b>
	)		
<b>Application No.:</b>	)	<b>Art Unit:</b>	<b>3763</b>
	)		
<b>Date Filed:</b>	)	<b>Examiner:</b>	<b>Catherine S. Williams</b>
	)		
<b>Title:</b>	)	<b>Customer No.:</b>	<b>23448</b>
	)		
<b>INFLATABLE DUAL BALLOON CATHETER</b>	)		

**FACSIMILE TRANSMISSION CERTIFICATE****ATTN: Examiner Catherine S. Williams****Fax No. (571) 273-8300**

I hereby certify that this document, along with any enclosures identified herein, is being filed in the United States Patent and Trademark Office, via facsimile transmission to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date specified below, to United States Patent and Trademark Office facsimile transmission number (571) 273-8300.

**2**

Number of Pages (including cover)

  
Vincent K. Gustafson

October 26, 2006

Date

**STATEMENT OF SUBSTANCE OF INTERVIEW CONDUCTED ON  
SEPTEMBER 29, 2006 IN U.S. PATENT APPLICATION NO. 10/622,275**

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

OCT 26 2006

4179-123

This responds to the Office Communication dated October 6, 2006 in which Applicant was requested to file a statement of the substance of the interview conducted on September 29, 2006 in the above-referenced application by the deadline of November 6, 2006.


The undersigned telephoned the examiner on September 29, 2006 to discuss the Office Action dated August 29, 2006. In that Office Action, the examiner stated

"the arguments are not persuasive, the hemostatic material of the Lentz reference is capable of treating hemorrhage conditions. The current claims [50 and 52-56] lack enough structural and functional language to overcome the prior art of record"

The undersigned identified a problem with the rejection of independent claim 50 in that such claim did *not recite any "hemostatic material,"* which was indicated to be the basis for maintaining the rejection of the pending claims.

The examiner acknowledged that claim 50 did not recite any hemostatic material, and agreed to re-evaluate the rejection the pending claims 50 and 52-56 over the cited art.

Respectfully submitted,

  
\_\_\_\_\_  
Vincent K. Gustafson  
Reg. No. 46,182  
Attorney for Applicants

INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW  
Phone: (919) 419-9350  
Fax: (919) 419-9354  
Attorney File No.: 4179-123

The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284